Sareum Share News (SAR)

Sareum Shares Drop As Pretax Loss Widens

LONDON (Alliance News) - Shares in Sareum Holdings PLC slid 12% Wednesday as its pretax loss widened in the half-year ended December 31, 2013. The specialist cancer drug discovery and development business posted a pretax loss of GBP375,000, widened from GBP305,000 in the previous year, due

Sareum Receives Patent As It Progresses Cancer Treatment To Trials

LONDON (Alliance News) - Sareum Holdings PLC said Wednesday that it had received a patent from the US Patent and Trademark Office for one of the inventions associated to its CHK1 cancer treatment programme. The patent covers compounds developed by Sareum and Cancer Research UK-funded scient

Sareum Holdings does cancer drug deal in China

Cancer drug developer Sareum Holdings has signed a deal with a Chinese medical university to progress its Aurora+FLT3 cancer programme. Sareum has granted the Hebei Medical University Biomedical Engineering Center exclusive rights to carry out pre-clinical and clinical studies within Greater China

UK WINNERS & LOSERS: Vodafone Up But Meggitt Slides After Warning

Sareum raises funds for further drug development

Sareum Holdings, a cancer drug discovery and development business, has placed 278.5m shares at 0.6p each, it announced Friday. The group raised a conditional £1.67m before expenses from the placing, which it said was oversubscribed. The proceeds of the placing will provide funds to facilitate the

CORRECT: Sareum Slides After Placing To Raise Funds For Development Programmes

Sareum Slides After Placing To Raise Funds For Development Programmes

Sareum Holdings In Co-Development Deal For Cancer Treatment

Sareum Holdings and SRI International develop drug for inflammatory diseases

Cancer drug discovery business Sareum Holdings has entered into a co-development agreement with research institute SRI International. The two have joined forces to advance Sareum's Tyrosine Kinase 2 (TYK2) small molecule drug discovery programme for readiness in human clinical trials. Research wi

Sareum shares fall following interims and research update

Shares in AIM-listed Sareum Holdings, the specialist cancer drug discovery business, fell sharply on Monday morning after the company unveiled its half yearly results alongside a research update. Cash at bank as of December 31st fell 28% to £380,000 and the company reported a loss on ordinary activ

Sareum share price climbs on US patent grant announcement

The share price of AIM-listed specialist cancer drug discovery business Sareum Holdings jumped sharply on Thursday after the company announced that a patent was due to be awarded in the US for one of its key drug discovery inventions. The patent, which is expected on February 19th, relates to compo

Sareum share price plummets ahead of AGM

The likelihood that specialist cancer drug discovery business Sareum will conclude a deal to commercialise a research programme this year has fallen, according to an announcement made ahead of its annual general meeting (AGM) on Wednesday morning. During the AGM, Dr. Paul Harper, the company's Chai

Small caps round-up: Sareum, Lonrho, FFastFill

Sareum, a specialist cancer drug discovery business, has entered into a four million pound Standby Equity Distribution Agreement (SEDA) with YA Global Master, an investment fund to provide a flexible source of future funding to the company to support its on-going drug research activities. It will a

Small caps round-up: YouGov, Sareum and InterQuest...

Environmental Recycling Technologies, which owns the rights to the Powder Impression Moulding (PIM) process which is capable of converting mixed waste plastics into commercially viable products, has confirmed that its US parent application, entitled 'Process for Forming Plastic, Apparatuses for Form

Small caps round-up: Byotrol, sareum, KDD ...

Byotrol, an anti-microbial hygiene company, has continued to make progress and has maintained the momentum seen in the second half of last year into the current financial year. The balance sheet continues to remain strong and is well positioned to its objective of positive cash generation at the ear